Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy

15/6/2024 13:01

        The Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.
        
        Senator Bernie Sanders, who chairs the committee, said, a U.S. Senate health panel vote that was scheduled for its June 18 meeting, to decide whether to subpoena Novo to answer questions about U.S. prices for the blockbuster drugs, is no longer necessary and will be canceled.
        
        The subpoena would have required Novo President Doug Langa to testify at a July 10 hearing.
        
        Jorgensen will testify before the committee, and the hearing will be held in early September.
        
        Sanders said, Novo charges Americans $1,349 a month for Wegovy, while it can be purchased for $140 in Germany and $92 in the UK.